Journalists Talk New ‘MAHA’ Strategy, RFK Jr.’s Tack at HHS, and Plight of Rural Hospitals

KFF Health News correspondent Rachana Pradhan discussed Health and Human Services Secretary Robert F. Kennedy Jr.’s new “Make America Healthy Again” strategy for children’s health on CBS News’ “CBS Morning News” on Sept. 10. Click here to watch Pradhan on “CBS Morning News.” KFF Health News chief Washington correspondent Julie Rovner discussed Kennedy’s pseudoscientific approach…

Read More

Types of uncertainty in health economic modelling

There are four primary types of uncertainty in health economic modelling: Heterogeneity: Variation between individuals that can be explained by their characteristicsStochastic uncertainty: Variation between individuals that cannot be explained by their characteristics, Parameter uncertainty: Uncertainty in the estimated values for the parameters that define the modelStructural uncertainty: Uncertainty in model outcomes that arise from…

Read More

Do people like to daydream?

Not really. At least according a study by Wilson et al. 2025 in Science. In 11 studies, we found that participants typically did not enjoy spending 6 to 15 minutes in a room by themselves with nothing to do but think, that they enjoyed doing mundane external activities much more, and that many preferred to…

Read More

Links

Sarah Emond on Prescription for Better Access. “Nothing will have more impact on workers’ comp than significant cuts to Medicaid.”“So one can only assume that we’re not picking flu strains this year.”SLR: Palliative care effectiveness/cost effectivenessNBER: Economics of Artificial Intelligence

Read More

ISPOR 2025 Award Winners

ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…

Read More

Pharvaris Drug for Rare Swelling Disease Meets Phase 3 Goals; FDA Filing Planned for 2026

Pharvaris’s deucrictibant met the main and secondary goals of its Phase 3 test as an on-demand treatment for swelling attacks caused by the rare disease hereditary angioedema. Pharvaris’s capsule could compete against Kalvista Pharmaceuticals’ Ekterly, an HAE pill approved by the FDA over the summer. The post Pharvaris Drug for Rare Swelling Disease Meets Phase…

Read More